This study includes a safety run in and a cohort expansion. The safety run in will include patients with any of the indications under study including:~Recurrent or persistent platinum-resistant epithelial ovarian cancer (EOC), including primary peritoneal and fallopian tube carcinoma Recurrent, metastatic, or persistent cervical carcinoma Advanced or recurrent endometrial cancer~Cohort expansion will include patients with advanced malignancies who have received at least two prior systemic therapies in the same indications.
This is a first-in-human Phase 1 multicenter, open-label oncology study designed to evaluate the safety and efficacy of NX-DeTIL-0255-201 in patients with advanced malignancies.